The hope and fear of rimonabant.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of the American Medical Association (JAMA)

• Publication date

  2008-04-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jama.299.13.1601PMID 18387935
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.

  2008cited by this paper
• Intravascular ultrasound for the evaluation of therapies targeting coronary atherosclerosis.

  2007cited by this paper
• Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.

  2007cited by this paper
• Effect of torcetrapib on the progression of coronary atherosclerosis.

  2007cited by this paper
• Cause-specific excess deaths associated with underweight, overweight, and obesity.

  2007cited by this paper
• Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.

  2006cited by this paper
• Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

  2006cited by this paper
• Prevalence of overweight and obesity in the United States, 1999-2004.

  2006cited by this paper
• Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks.

  2006cited by this paper
• Depression and cardiovascular disease: a call for recognition.

  2005cited by this paper
• Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

  2005cited by this paper
• Years of life lost due to obesity.

  2003cited by this paper

• Is poor dose selection undermining the translational validity of antidepressant research involving animal models?

  2025cites this paper
• Effects of the cannabinoid CB1-receptor neutral antagonist AM4113 and antagonist/inverse agonist rimonabant on fentanyl discrimination in male rats.

  2022cites this paper
• Effects of pro-depressant and immunomodulatory drugs on biases in decision-making in the rat judgement bias task

  2020cites this paper
• Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly

  2018cites this paper
• Translational new approaches for investigating mood disorders in rodents and what they may reveal about the underlying neurobiology of major depressive disorder

  2018cites this paper
• Endocannabinoids, Stress, and Negative Affect

  2017cites this paper
• Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice

  2017cites this paper
• Improving the Translational Validity of Methods Used to Study Depression in Animals

  2016cites this paper
• A RESINA DE Protium heptaphyllum E SEU PRINCIPAL CONSTITUINTE, A MISTURA DE TRITERPENOS ALFA E BETA-AMIRINA, PREVINEM A OBESIDADE INDUZIDA POR DIETA EM CAMUNDONGOS: EVIDÊNCIAS E POTENCIAIS MECANISMOS

  2015cites this paper
• Distinct Neuropsychological Mechanisms May Explain Delayed- Versus Rapid-Onset Antidepressant Efficacy

  2015cites this paper
• A Translational Rodent Assay of Affective Biases in Depression and Antidepressant Therapy

  2013influential citation
• Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity

  2013cites this paper
• Inflammation in type 2 diabetes and the neuroendocrine role of IL-18

  2013cites this paper
• Cannabinoids: Chemistry and Medicine

  2013cites this paper
• Reasons for and time to discontinuation of rimonabant therapy: a modified prescription-event monitoring study.

  2012cites this paper
• Reasons for and Time to Discontinuation of Rimonabant Therapy

  2012influential citation
• Prefrontal endocannabinoid signaling mediates neuroendocrine and behavioral coping responses to stress

  2012cites this paper
• Reports of the death of CB1 antagonists have been greatly exaggerated: recent preclinical findings predict improved safety in the treatment of obesity

  2012cites this paper
• Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk

  2011cites this paper
• Cannabinoids: occurrence and medicinal chemistry.

  2011cites this paper
• Contribution of Pharmacology to Development of Monoaminergic Hypotheses of Depression

  2011cites this paper
• Pharmakologische Strategien zur Unterstützung einer Raucherentwöhnung

  2011cites this paper
• Addressing tobacco use disorder in smokers in early remission from alcohol dependence: the case for integrating smoking cessation services in substance use disorder treatment programs.

  2010cites this paper
• Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.

  2010cites this paper
• A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain.

  2009cites this paper
• Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.

  2009cites this paper
• Obesity, the Endocannabinoid System, and Bias Arising from Pharmaceutical Sponsorship

  2009cites this paper
• Recent advances in obesity pharmacotherapy.

  2009cites this paper
• Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: Drug-discovery strategies

  2009cites this paper
• The associative representation of fear memories mediated by the amygdala

  2009cites this paper
• Trial comes too late as psychiatric side effects end hope for rimonabant.

  2009cites this paper
• Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis

  2009influential citation
• STRADIVARIUS: a brave trial aimed at clarifying benefits of rimonabant therapy.

  2008cites this paper
• Rimonabant: perspectives and controversies

  2008cites this paper
• The medical geography of cannabinoid botanicals in Washington State: Access, delivery, and distress

  2008cites this paper
• Hamilelik ve laktasyon döneminde antiobezitik ilaç kullan›m›n›n toksikolojik aç›dan deerlendirilmesi

  2008cites this paper
• [Sleep disorders associated with treatment with rimonabant].

  2008cites this paper
• Rimonabant and progression of atherosclerosis in obese persons.

  2008cites this paper
• El rimonabant no detiene la progresión de la placa de ateroma en pacientes con cardiopatía isquémica y obesidad central

  2008cites this paper
• PRE- AND POST-MARKETING PHARMACOVIGILANCE: THE MYTHS OF THE PLACEBO EFFECTS AND OF THE OFF-LABEL USE OF DRUGS.°

  2008cites this paper